Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved NEVANAC til forebyggelse og lindring af smerter og betændelseslignende tilstand efter operation for grå stær opvejer risiciene.
The Committee for Medicinal Products for Human Use (CHMP) decided that NEVANAC’ s benefits are greater than its risks for prevention and treatment of postoperative pain and inflammation associated with cataract surgery.